Clinical Trial Update: Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing immunogenicity and safety of Boostrix using a new syringe in adolescents aged 10 to 15 years; results completed and posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Tetanus

Drugs mentioned

• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diphtheria, Tetanus | Phase 4 | Status: COMPLETED | Results posted: 2018-08-10